Results 11 to 20 of about 1,145 (113)

Monomorphic ventricular tachycardia due to protease inhibitor intoxication by atazanavir [PDF]

Clinical and Experimental Emergency Medicine, 2018
Atazanavir is a protease inhibitor approved for use in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus infection.
Byunghyun Kim, Kyung Su Kim
doaj   +1 more source

Coadministration of Atazanavir-Ritonavir and Zinc Sulfate: Impact on Hyperbilirubinemia and Pharmacokinetics [PDF]

Antimicrobial Agents and Chemotherapy, 2013
ABSTRACT Atazanavir (ATV) causes an elevation of unconjugated hyperbilirubinemia (HBR) as a result of UDP glucuronyltransferase (UGT) 1A1 inhibition. Zinc sulfate (ZnSO 4 ) reduces unconjugated hyperbilirubinemia in individuals with Gilbert's syndrome.
Graeme, Moyle, Laura, Else, Akil, Jackson, David, Back, Manisha H, Yapa, Natalia, Seymour, Lisa, Ringner-Nackter, Zeenat, Karolia, Brian, Gazzard, Marta, Boffito   +9 more
openaire   +2 more sources

A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus

Microbial Biotechnology, Volume 16, Issue 11, Page 2036-2052, November 2023., 2023
HSV glycoproteins gC, gB, gD, gH and host cell receptors such as HSPG, nectin and HVEM can be used as targets to develop antiviral agents. By using proteins or peptides derived from these glycoproteins and receptors, it is possible to create decoys that can inhibit HSV attachment, entry, or fusion.
Rakesh Rahangdale, Tenzin Tender, Sridevi Balireddy, Kamini Goswami, Mukesh Pasupuleti, Raghu Chandrashekar Hariharapura   +5 more
wiley   +1 more source

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

Thoracic Cancer, Volume 14, Issue 27, Page 2804-2810, September 2023., 2023
The combination of weekly irinotecan and S‐1 was not superior to single‐agent therapy in terms of ORR, although the toxicity profile was as expected. This combination did not yield the expected effects and may not be a candidate regimen for future phase III trials. Abstract Background This phase II trial was designed to evaluate the efficacy and safety
Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara   +7 more
wiley   +1 more source

Physiologic Changes During Pregnancy and Impact on Small‐Molecule Drugs, Biologic (Monoclonal Antibody) Disposition, and Response

The Journal of Clinical Pharmacology, Volume 63, Issue S1, Page S34-S50, June 2023., 2023
Abstract Pregnancy is a unique physiological state that results in many changes in bodily function, including cellular, metabolic, and hormonal changes. These changes can have a significant impact on the way small‐molecule drugs and monoclonal antibodies (biologics) function and are metabolized, including efficacy, safety, potency, and adverse effects.
Ahizechukwu C. Eke, Rahel D. Gebreyohannes, Maria Fernanda Scantamburlo Fernandes, Venkateswaran C. Pillai   +3 more
wiley   +1 more source

Nanostructured Lipid Carriers for Improved Delivery of Therapeutics via the Oral Route

Journal of Nanotechnology, Volume 2023, Issue 1, 2023., 2023
Drug delivery via the oral route has always been challenging for poorly soluble drugs. Acid‐induced hydrolysis, enzymatic degradation, and poor mucosal absorbency remain the primary hiccups for effective oral delivery of medications. With the advent of nanotechnology, nanostructured lipid carriers (NLCs) have emerged as a promising delivery carrier ...
Alok Kumar Mahor, Prem Prakash Singh, Rishikesh Gupta, Peeyush Bhardwaj, Priyanka Rathore, Ankita Kishore, Rohit Goyal, Neeraj Sharma, Jyoti Verma, Jessica M. Rosenholm, Kuldeep K. Bansal, Nasrullah Jan   +11 more
wiley   +1 more source

FORMULATION AND EVALUATION OF FIXED-DOSE COMBINATION OF BILAYER TABLETS OF ATAZANAVIR SULFATE AND RITONAVIR 300 MG/100 MG

International Journal of Applied Pharmaceutics, 2021
Objective: The objective of this study is to formulation and development of fixed-dose combination as a single dosage regimen by using the design of experiments (DOE) approach against the single dose of reference listed drugs of brand reyataz capsule 300 mg (atazanavir sulfate) and norvir tablets 100 mg (ritonavir tablets) to treat human ...
JONNA SANKARAIAH, NEERAJ SHARMA, MOHD JAVED NAIM   +2 more
openaire   +2 more sources

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

AIDS Research and Therapy, 2009
Background Traditional first line regimens containing a non-nucleoside reverse transcriptase inhibitor or protease inhibitor may not be suitable for a subset of antiretroviral-naïve patients such as those with certain co-morbidities, women of child ...
McClernon Daniel, Patel Parul, DeJesus Edwin, LaMarca Anthony, Salvato Patricia, Kumar Princy N, Florance Allison, Shaefer Mark S   +7 more
doaj   +1 more source

Hemoperfusion Combined With Continuous Renal Replacement Therapy in the Management of ARDS COVID-19 Patients: A Quasi-Experimental Study. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Critically ill patients in COVID‐19 to the intensive care unit (ICU) may develop multiple organ dysfunction syndrome, with some requiring extracorporeal organ support. This study aimed to assess the effects of combined CytoSorb hemoperfusion (HP) and continuous renal replacement therapy (CRRT) on the improvement of the ...
Hashemian SM, Jafari A, Khoundabi B, Jamaati H, Rahimi P.   +4 more
europepmc   +2 more sources

DEVELOPMENT AND VALIDATION OF STABILITY INDICATING NEW RP-HPLC METHOD FOR THE DETERMINATION OF ATAZANAVIR SULFATE IN BULK AND CAPSULE DOSAGE FORM

Journal of Advanced Scientific Research, 2021
A new stability indicating RP-HPLC method was developed and validated for the determination of Atazanavir sulfate in bulk and capsule dosage form on Zorbax Eclipse XDB C18 (150x 4.6mm) 3.5 μm column. Elution was carried using mobile phase consists of phosphate buffer pH 6.5: acetonitrile (40:60 v/v) at column temperature of 30˚C.
Amol Warokar, Ujwala Mahajan, Laxmicant Barde, Nitin Charbe, Sanket Supare   +4 more
openaire   +1 more source